ABL Bio (Korea) Investor Sentiment

298380 Stock  KRW 27,050  600.00  2.17%   
About 62% of ABL Bio's investor base is looking to short. The analysis of current outlook of investing in ABL Bio suggests that many traders are alarmed regarding ABL Bio's prospects. The current market sentiment, together with ABL Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use ABL Bio stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates - Ya...
Google News at Macroaxis
over six months ago at news.google.com         
ABL Bio Full Year 2023 Earnings EPS Beats Expectations - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Biotheus, Hansoh ink potential 5B deal for new bispecific ADCs - BioWorld Online
Google News at Macroaxis
over six months ago at news.google.com         
I-Mab Reports Full Year 2023 Financial Results and Business Update - PR Newswire
Google News at Macroaxis
over six months ago at news.google.com         
Bio shares, which have been on the rise recently, are leading the KOSDAQs rise. Ahead of major conf....
Google News at Macroaxis
over six months ago at news.google.com         
Is ABL Bio Weighed On By Its Debt Load - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Is ABL Bio Weighed On By Its Debt Load - Simply Wall St
Google News at Macroaxis
over six months ago at news.google.com         
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutral...
Google News at Macroaxis
over six months ago at news.google.com         
Ascentage Pharma Hosts Ceremony Marking the Launch of ... - BioSpace
Google News at Macroaxis
over a year ago at news.google.com         
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023 - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
GenScript ProBio Congratulates ABL Bios IND Clearance of ABL103 Program from MFDS - PR Newswire
Google News at Macroaxis
over a year ago at news.google.com         
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14BABL503 - Yah...
Google News at Macroaxis
over a year ago at news.google.com         
ABL Bio Taps into Synaffix ADC Technology to Accelerate ... - PR Newswire
Google News at Macroaxis
over a year ago at news.google.com         
GBC 2023 In generative AI era, collaboration key for drug discovery - BioWorld Online
Google News at Macroaxis
over a year ago at news.google.com         
The ABL-MYC axis controls WIPI1-enhanced autophagy in lifespan ... - Nature.com
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about ABL Bio that are available to investors today. That information is available publicly through ABL media outlets and privately through word of mouth or via ABL internal channels. However, regardless of the origin, that massive amount of ABL data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ABL Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ABL Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ABL Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ABL Bio alpha.

ABL Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for ABL Stock analysis

When running ABL Bio's price analysis, check to measure ABL Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABL Bio is operating at the current time. Most of ABL Bio's value examination focuses on studying past and present price action to predict the probability of ABL Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABL Bio's price. Additionally, you may evaluate how the addition of ABL Bio to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital